This profile confers selective dependencies in OXPHOS-dep. tRCC cells. e.g tRCCs show selective dep on EGLN1. Inhibiting EGLN1 stabilizes HIF-1α, leading to glycolytic reprogramming. EGLN inhibitors, approved for anemia treatment, could perhaps be explored for tRCC & other OXPHOS-high cancers 💊. 3/

Excited to share our new study on translocation RCC (tRCC) in collaboration with @liron1bar-peled.bsky.social. We reveal how the TFE3 fusion drives a key oxidative phosphorylation (OXPHOS) metabolic program in this rare kidney cancer. trebuchet.public.springernature.app/get_content/... 1/